ERBB2 and neoplasm: A representative HER2 3+ tumor specimen is shown in Figure 5, with strong, complete membranous staining of tumor cells, consistent with ASCO/CAP criteria for HER2 positivity and eligibility for targeted anti-HER2 therapy.